Pliant Q2 Loss Narrows, Cash Runway Extended to H2 2028 as Oncology Pipeline Advances

summarizeSummary

Pliant Therapeutics reported a narrower Q2 loss and extended its cash runway into H2 2028, while its lead oncology program showed encouraging early progress.

check_boxKey Events · Earnings and Guidance · PLRX

• Q2 Loss Narrows Sharply

  Net loss fell to $22.4M from $43.3M in Q2 2025, driven by the discontinuation of bexotegrast and workforce reductions. Operating expenses dropped 48% year-over-year.

• Cash Runway Extended to H2 2028

  Cash, equivalents, and short-term investments totaled $159.6M at June 30, 2026. Management believes this is sufficient to fund operations for at least the next 12 months and into the second half of 2028.

• FORTIFY Trial Enrollment Ahead of Schedule

  The Phase 1b trial of PLN-101095 in solid tumors is enrolling ahead of plan across three cohorts. Interim data is expected in 2027.

• Biomarker Data Supports Oncology Pivot

  Updated Phase 1 data presented at AACR showed PLN-101095 monotherapy triggered a coordinated T-cell reactivation cascade in responders, with increases in IFN-γ, CXCL9, and granzyme-B.

auto_awesomeAnalysis · PLRX · Life Sciences

Pliant's Q2 results show a sharply reduced net loss of $22.4M, down from $43.3M a year ago, driven by the wind-down of the failed bexotegrast program and restructuring. Cash of $159.6M now funds operations into the second half of 2028, removing near-term survival risk. The oncology pivot is gaining traction: enrollment in the FORTIFY Phase 1b trial of lead asset PLN-101095 is ahead of schedule, and new biomarker data presented at AACR strengthens the scientific rationale. An option repricing at $1.33 and an untapped $50M ATM provide additional financial flexibility. The stock trades near its 52-week low, so the extended runway and clinical progress are critical offsets to the company's challenged history.